Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Basilea PharmaceuticaFRA:PK5 -0.34%59 Days Payable is 150.73 as of Dec. 2025, which is 35% above its 10-year median of 111.86. GuruFocus rates FRA:PK5 with a GF Score™ of 59/100 and a GF Value™ of €62.49 (Fairly Valued). The stock has 4 warning signs investors should review. Among 701 Biotechnology companies, Basilea Pharmaceutica ranks worse than 50.07% on this metric.
Basilea Pharmaceutica Days Payable Historical Data
* Premium members only.
The historical data trend for Basilea Pharmaceutica's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PK5 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Basilea Pharmaceutica's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basilea Pharmaceutica Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Days Payable distribution charts can be found below:
* The bar in red indicates where Basilea Pharmaceutica's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Basilea Pharmaceutica's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basilea Pharmaceutica (FRA:PK5) has a Days Payable of 150.73 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Basilea Pharmaceutica and its competitors. This is 35% above median its historical median of 111.86. Over the past decade, Basilea Pharmaceutica's Days Payable has ranged from 41.13 to 180.20. According to the industry distribution chart, Basilea Pharmaceutica ranks #351 out of 701 companies in the Biotechnology industry, placing it in the top 50.1%.
Is Basilea Pharmaceutica's Days Payable too high?
Basilea Pharmaceutica's current Days Payable of 150.73 is 35% above median its 10-year median of 111.86. Over the past 10 years, this metric has ranged from a low of 41.13 to a high of 180.20. The Biotechnology industry median Days Payable is 112.84. Basilea Pharmaceutica's value of 150.73 is 33.6% above this industry median. Based on the distribution chart, Basilea Pharmaceutica ranks #351 out of 701 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Basilea Pharmaceutica has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Basilea Pharmaceutica ranks #351 out of 701 companies for Days Payable. This places Basilea Pharmaceutica in the lower half of its industry. The industry median Days Payable is 112.84. Basilea Pharmaceutica's value of 150.73 is 33.6% above this benchmark. Historically, Basilea Pharmaceutica's own Days Payable has ranged from 41.13 to 180.20 over the past decade. While the company's 10-year median is 111.86 vs. the industry median of 112.84, Basilea Pharmaceutica has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Basilea Pharmaceutica's current Days Payable of 150.73 is 33.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Basilea Pharmaceutica and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basilea Pharmaceutica's current Days Payable is 150.73, which is 35% above median its own 10-year median of 111.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (FRA:PK5) is currently considered Fairly Valued. The stock's GF Value™ is €62.49, compared to a current price of €59.10 — trading 5.4% below its estimated fair value. The current Days Payable is 150.73, which is 35% above median its 10-year median of 111.86 and 33.6% above the Biotechnology industry median of 112.84. Basilea Pharmaceutica's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Basilea Pharmaceutica (FRA:PK5), the current Days Payable is 150.73 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Basilea Pharmaceutica (FRA:PK5) Overvalued in 2026?
Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued.
The current stock price of €59.10 is trading 5.4% below its estimated GF Value™ of €62.49.
GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.
Key valuation signals for FRA:PK5:
Days Payable: 150.73 (35% above median its 10-year median of 111.86)
GF Value™: €62.49 vs. price of €59.10 (5.4% below fair value)
Industry Position: 33.6% above the Biotechnology median (#351 of 701)
No single metric tells the full story. See the FRA:PK5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
59GF Score
Get the complete analysis for FRA:PK5
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PK5 has been successfully added to your 
